Core Insights - Baxter International Inc. reported fourth-quarter 2025 adjusted earnings per share (EPS) of 44 cents, missing the Zacks Consensus Estimate of 53 cents by 17% and declining 24% from the previous year [1][7] - On a GAAP basis, the company reported a loss per share of $2.19 compared to a loss of 95 cents in the prior-year quarter [1] Revenue Performance - Revenues from continuing operations totaled $2.97 billion, reflecting an 8% increase on a reported basis and a 3% increase on an operational basis, surpassing the Zacks Consensus Estimate by 6.5% [3] - U.S. sales from continuing operations were $1.55 billion, up 3% on a reported basis but down 1% on an operational basis [3] - International sales from continuing operations reached $1.42 billion, showing a 14% increase on a reported basis and an 8% increase on an operational basis [3] Segment Analysis - Medical Products & Therapies segment sales totaled $1.39 billion, up 6% reported and 4% operationally, driven by strong demand in Infusion Therapies & Technologies and Advanced Surgery products [5] - Infusion Therapies and Technologies sales were $1.06 billion, up 4% year over year reported and 1% operationally [8] - Healthcare Systems and Technologies segment sales were $827 million, up 5% year over year reported and 4% operationally [9] - Pharmaceuticals segment sales were $668 million, up 4% year over year reported and 2% operationally, with growth driven by Drug Compounding [10] Margin and Expense Analysis - Adjusted gross profit was $1.06 billion, down 13.9% year over year, with adjusted gross margin contracting 900 basis points to 35.5% [11] - Adjusted operating income from continuing operations totaled $352 million, down 16% year over year, with adjusted operating margin contracting 340 basis points to 11.8% [12] 2026 Guidance - Baxter expects 2026 sales to be flat to up 1% on a reported basis, with adjusted EPS projected in the range of $1.85-$2.05, below the Zacks Consensus Estimate of $2.33 [13]